World's Best Scientists 2026 revealed!
Lewis B. Silverman

Lewis B. Silverman

D-Index & Metrics

Medicine

D-Index
94
Citations
36511
World Ranking
10400
National Ranking
5355

Overview

Lewis B. Silverman is affiliated with Harvard University in the United States and has contributed extensively to the field of medicine, with a particular focus on acute lymphoblastic leukemia and related pediatric health issues. Their research output encompasses a wide range of topics within medicine, reflecting a strong interdisciplinary approach centered on oncology and child health.

The scientist's research spans several interconnected fields of study including public health, environmental and occupational health, pediatrics, perinatology and child health, hematology, oncology, and speech and hearing. This multidisciplinary engagement highlights their broad interest in both the biological and clinical aspects of disease as well as patient quality of life.

Lewis B. Silverman's scholarly work largely concentrates on the following main topics:

  • Acute Lymphoblastic Leukemia research
  • Childhood Cancer Survivors' Quality of Life
  • Adolescent and Pediatric Healthcare
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research

Recent papers authored or co-authored by Silverman demonstrate a focus on clinical guidelines, treatment outcomes, and molecular characterizations of leukemia. These include:

  • Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study, 2020, Journal of Clinical Oncology
  • Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL, 2020, Blood
  • Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001, 2021, Blood Advances
  • Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001, 2021, Journal of Clinical Oncology

Collaborations form an important part of Silverman's research activities, with frequent co-authors including Peter D. Cole, Kara M. Kelly, Jennifer J.G. Welch, Andrew E. Place, and Kristen E. Stevenson. The repeated collaboration with these researchers suggests a networked approach to clinical and translational oncology research.

Silverman's work has been published predominantly in specialized venues that address hematology, oncology, and pediatric cancer research. The primary publication venues include:

  • Blood
  • Pediatric Blood & Cancer
  • Journal of Clinical Oncology
  • Blood Advances
  • Cancer Epidemiology Biomarkers & Prevention

The body of work attributed to Lewis B. Silverman encompasses more than two hundred publications, affirming a focused research career in medicine with an emphasis on the clinical, molecular, and quality-of-life dimensions of leukemia and pediatric oncology.

Best Publications

  • Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

    Andrew P. Weng;Andrew P. Weng;Adolfo A. Ferrando;Adolfo A. Ferrando;Woojoong Lee;Woojoong Lee;John P. Morris;John P. Morris

  • Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia

    Todd R. Golub;Scott A. Armstrong;Stanley J. Korsmeyer

  • Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

    Lewis B. Silverman;Richard D. Gelber;Virginia Kimball Dalton;Barbara L. Asselin

  • Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

    Ching Hon Pui;Jun J. Yang;Stephen P. Hunger;Rob Pieters

  • An Oncogenic Super-Enhancer Formed Through Somatic Mutation of a Noncoding Intergenic Element

    Marc R. Mansour;Marc R. Mansour;Brian J. Abraham;Lars Anders;Alla Berezovskaya

  • Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia

    M Arico;MG Valsecchi;B Camitta;M Schrappe

  • A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

    Rob Pieters;Martin Schrappe;Paola De Lorenzo;Ian Hann

  • The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia

    Steven E. Lipshultz;Nader Rifai;Virginia M. Dalton;Donna E. Levy

  • L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

    Rob Pieters;Stephen P. Hunger;Joachim Boos;Carmelo Rizzari

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias

    Andrei V. Krivtsov;Zhaohui Feng;Madeleine E. Lemieux;Joerg Faber

  • Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

    Albert Moghrabi;Donna E. Levy;Barbara L. Asselin;Ronald Barr

  • Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

    Steven E Lipshultz;Rebecca E Scully;Stuart R Lipsitz;Stephen E Sallan;Stephen E Sallan

  • Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification

    Scott A Armstrong;Andrew L Kung;Andrew L Kung;Meghann E Mabon;Lewis B Silverman;Lewis B Silverman

  • Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region

    Ching-Hon Pui;Paul S Gaynon;James M Boyett;Judith M Chessells

  • High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

    Alejandro Gutierrez;Alejandro Gutierrez;Takaomi Sanda;Ruta Grebliunaite;Arkaitz Carracedo

  • Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation

    Adolfo A. Ferrando;Scott A. Armstrong;Donna S. Neuberg;Stephen E. Sallan

  • Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience

    John M. Goldberg;Lewis B. Silverman;Donna E. Levy;Virginia Kimball Dalton

  • Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

    Lynda M. Vrooman;Kristen E. Stevenson;Jeffrey G. Supko;Jane O'Brien

  • Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985―2000)

    Lewis B. Silverman;Kristen E. Stevenson;Jane E. O’Brien;Barbara L. Asselin

Frequent Co-Authors

Stephen E. Sallan
Stephen E. Sallan Harvard University
Donna Neuberg
Donna Neuberg Harvard University
Stephen P. Hunger
Stephen P. Hunger University of Pennsylvania
Mignon L. Loh
Mignon L. Loh University of California, San Francisco
Steven E. Lipshultz
Steven E. Lipshultz University at Buffalo, State University of New York
Daniel J. DeAngelo
Daniel J. DeAngelo Harvard University
Ching-Hon Pui
Ching-Hon Pui St. Jude Children's Research Hospital
A. Thomas Look
A. Thomas Look Harvard University
Rob Pieters
Rob Pieters Princess Máxima Center
Jeffery L. Kutok
Jeffery L. Kutok Epizyme (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online healthcare degrees is an excellent way to fast-track your career or advance your current skills. Many nursing professionals wonder, for example, does rn to bsn require clinicals? Some flexible RN to BSN programs may allow you to earn your degree entirely online, while others include clinical requirements, making it important to verify the details before enrolling.

For nurses with a master's degree, there are also options to complete a shortest post master's dnp program, accelerating your pathway to a Doctor of Nursing Practice (DNP) in as little as one year. If you are searching for the fastest route overall, some of the shortest dnp program choices focus on working professionals and emphasize practical, leadership-oriented coursework.

Entry-level options also exist. Aspiring nurses can enroll in fast track lpn programs online and quickly qualify for licensure, often in a matter of months. Online healthcare education continues to evolve, offering options for both newcomers and experienced clinicians to reach their goals efficiently.

Best Scientists Citing Lewis B. Silverman

Trending Scientists

Recently Published Articles